Olink case study in cancer immunotherapy
This study, carried out in collaboration with the Massachusetts General Hospital Cancer Center, performed deep proteomic profiling together with single-cell RNAseq in a metastatic melanoma cohort during Immune Checkpoint Blockade (ICB) treatment.
- Initial study: >700 proteins using Olink Target 96 panels
- Extended study: ~1500 proteins with the Olink Explore 1536 platform in an extended melanoma cohort comprising 200 patients.
- Results demonstrate the utility of blood-based protein biomarkers to predict treatment response